Reunion Neuroscience reports strong Phase 2 topline results for RE104 in postpartum depression across the RECONNECT trial

RE104 Phase 2 topline results for postpartum depression (PPD) come from Reunion Neuroscience’s RECONNECT trial, which enrolled 84 women with moderate to severe PPD across 38 U.S. sites. RE104 is presented as a prodrug of 4-OH-DiPT and is studied as a single-dose subcutaneous treatment delivered at 30 mg or 1.5 mg, with the lower dose positioned as an active control. Patients were followed for 28 days, and the primary endpoint is MADRS change from baseline to day 7. The report also frames RE104’s subjective experience duration as shorter than psilocybin but longer than faster-acting psychedelics such as DMT or 5-MeO-DMT, and notes that the first trial patient was dosed in July.